Scholar Rock Holding Corporation (SRRK)
SRRK Stock Price Chart
Explore Scholar Rock Holding Corporation interactive price chart. Choose custom timeframes to analyze SRRK price movements and trends.
SRRK Company Profile
Discover essential business fundamentals and corporate details for Scholar Rock Holding Corporation (SRRK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 May 2018
Employees
128.00
Website
https://scholarrock.comCEO
David L. Hallal
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Financial Timeline
Browse a chronological timeline of Scholar Rock Holding Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.83.
Earnings released on 6 Aug 2025
EPS came in at -$0.98 falling short of the estimated -$0.66 by -48.48%.
Earnings released on 14 May 2025
EPS came in at -$0.67 falling short of the estimated -$0.63 by -6.35%.
Earnings released on 27 Feb 2025
EPS came in at -$0.60 matching the estimated -$0.60.
Earnings released on 12 Nov 2024
EPS came in at -$0.66 falling short of the estimated -$0.58 by -13.77%.
Earnings released on 8 Aug 2024
EPS came in at -$0.60 surpassing the estimated -$0.61 by +1.64%.
Earnings released on 7 May 2024
EPS came in at -$0.59 falling short of the estimated -$0.51 by -15.69%.
Earnings released on 19 Mar 2024
EPS came in at -$0.50 falling short of the estimated -$0.49 by -2.04%, while revenue for the quarter reached $11.66M .
Earnings released on 7 Nov 2023
EPS came in at -$0.53 matching the estimated -$0.53.
Earnings released on 9 Aug 2023
EPS came in at -$0.47 surpassing the estimated -$0.56 by +16.07%.
Earnings released on 9 May 2023
EPS came in at -$0.49 surpassing the estimated -$0.57 by +14.04%.
Earnings released on 7 Mar 2023
EPS came in at -$0.46 surpassing the estimated -$0.58 by +20.69%, while revenue for the quarter reached $33.19M .
Earnings released on 14 Nov 2022
EPS came in at -$0.55 surpassing the estimated -$0.68 by +19.12%.
Earnings released on 8 Aug 2022
EPS came in at -$1.06 falling short of the estimated -$1.03 by -2.91%.
Earnings released on 16 May 2022
EPS came in at -$0.21 surpassing the estimated -$0.79 by +73.42%, while revenue for the quarter reached $33.19M , beating expectations by +49.98%.
Earnings released on 7 Mar 2022
EPS came in at -$0.97 surpassing the estimated -$1.04 by +6.73%, while revenue for the quarter reached $4.05M , missing expectations by -8.07%.
Earnings released on 9 Nov 2021
EPS came in at -$1.02 falling short of the estimated -$0.85 by -20.00%, while revenue for the quarter reached $5.46M , beating expectations by +17.76%.
Earnings released on 10 Aug 2021
EPS came in at -$0.84 falling short of the estimated -$0.78 by -7.69%, while revenue for the quarter reached $4.60M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$0.76 falling short of the estimated -$0.69 by -10.14%, while revenue for the quarter reached $4.71M , missing expectations by -18.83%.
Earnings released on 9 Mar 2021
EPS came in at -$0.79 falling short of the estimated -$0.62 by -27.42%, while revenue for the quarter reached $3.44M , missing expectations by -47.22%.
Earnings released on 9 Nov 2020
EPS came in at -$0.79 falling short of the estimated -$0.54 by -46.30%, while revenue for the quarter reached $3.04M , beating expectations by +2.85%.
SRRK Stock Performance
Access detailed SRRK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.